Mereu, E.; Abbo, D.; Paradzik, T.; Cumerlato, M.; Bandini, C.; Labrador, M.; Maccagno, M.; Ronchetti, D.; Manicardi, V.; Neri, A.;
et al. Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines. Cancers 2023, 15, 2199.
https://doi.org/10.3390/cancers15082199
AMA Style
Mereu E, Abbo D, Paradzik T, Cumerlato M, Bandini C, Labrador M, Maccagno M, Ronchetti D, Manicardi V, Neri A,
et al. Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines. Cancers. 2023; 15(8):2199.
https://doi.org/10.3390/cancers15082199
Chicago/Turabian Style
Mereu, Elisabetta, Damiano Abbo, Tina Paradzik, Michela Cumerlato, Cecilia Bandini, Maria Labrador, Monica Maccagno, Domenica Ronchetti, Veronica Manicardi, Antonino Neri,
and et al. 2023. "Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines" Cancers 15, no. 8: 2199.
https://doi.org/10.3390/cancers15082199
APA Style
Mereu, E., Abbo, D., Paradzik, T., Cumerlato, M., Bandini, C., Labrador, M., Maccagno, M., Ronchetti, D., Manicardi, V., Neri, A., & Piva, R.
(2023). Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines. Cancers, 15(8), 2199.
https://doi.org/10.3390/cancers15082199
